In T cells, CIS promotes CTL/Th1 development (94) through unknown mechanisms although it has been proposed that decreased CIS expression may lead to enhanced STAT5 activation, a transcription factor for Tregs, upsetting the Th1/Treg balance. The gene discussed is STAT5B; the disease is in situ carcinoma.